Chinese Journal of Tissue Engineering Research ›› 2010, Vol. 14 ›› Issue (18): 3271-3274.doi: 10.3969/j.issn.1673-8225.2010.18.010

Previous Articles     Next Articles

Treatment of bladder transitional cell carcinoma recurrence by transurethral resection followed by submucosal injection Epirubicin in renal transplantation recipients: Is it safe and effective?

Zhang Yong, Wang Yong, Zhang Xiao-dong, Li Xiao-bei, Yang Yong   

  1. Department of Urology, Beijing Chaoyang Hospital Affiliated to Capital Medical University, Beijing  100020, China
  • Online:2010-04-30 Published:2010-04-30
  • About author:Zhang Yong☆, Doctor, Associate chief physician, Associate professor, Master’s supervisor, Department of Urology, Beijing Chaoyang Hospital Affiliated to Capital Medical University, Beijing 100020, China doctorzhy@126.com

PDF

362

Abstract:

BACKGROUND: The renal transplanted recipients were in poor immunosuppressive state. Compared to common person, the bladder transitional carcinoma in recipients was aggressive and easy to recurrence. Looking for a more effective therapy method to decrease the recurrence of recipients’ bladder transitional carcinoma is the hot and difficult problem in clinical study.
OBJECTIVE: To analyze the efficacy and safety of submucosal injection epirubicin following transurethral resection of bladder tumor (TUR-Bt) to treat the recurrence of bladder transitional cell carcinoma in renal transplantation recipients.
METHODS: Totally 9 renal transplantation recipients with transitional cell carcinoma of bladder were retrospectively studied. The patients’ periods without cancer, the frequency of recurrence within one year, the rates of side effect, the changes of tumor grading following recurrence and allograft function were recorded when the routine method and submucosal injection epirubicin following TUR-Bt were used in different period respectively. 
RESULTS AND CONCLUSION: Submucosal injection epirubicin following transurethral resection of bladder tumor was safe and effective to treat bladder transitional cell carcinoma recurrence in renal transplantation recipients. Compared to the routine perfusion, periods without cancer and the frequency of recurrence within 1 year were significantly decreased, which can elevate recipients life quality and long-term survival rates.

CLC Number: